{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.67","upperLimit":"70.96","value":"28.6"},{"groupId":"OG001","lowerLimit":"4.33","upperLimit":"77.72","value":"33.3"},{"groupId":"OG002","lowerLimit":"4.33","upperLimit":"77.72","value":"33.3"}]}],"title":"sCR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.67","upperLimit":"70.96","value":"28.6"},{"groupId":"OG001","lowerLimit":"0.42","upperLimit":"64.12","value":"16.7"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"45.93","value":"0"}]}],"title":"CR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"CRR and sCRR were defined as the percentage of participants with CR or sCR, as determined by the investigator per IMWG response criteria. CR was defined as: no evidence of initial monoclonal protein isotype(s) on immunofixation of the serum \\& urine; Disappearance of any soft tissue plasmacytomas; \\<5% plasma cells in BM \\& a normal SFLC ratio of 0.26-1.65. sCR was defined as: CR (defined above); normal SFLC ratio, \\& absence of clonal cells in BM by IHC or negative by 2-4 color flow cytometry. CR and sCR are distinct response categories and are evaluated and reported separately in accordance with the defined response criteria i.e., if a response is clinically upgraded from CR to sCR it is not further considered a CR but solely a sCR. Percentages have been rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received step-up doses of forimtamig 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.3 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib, 20 mg/m\\^2 on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).","id":"OG000","title":"Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib"},{"description":"Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.75 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib 20 mg/m\\^2 on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).","id":"OG001","title":"Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib"},{"description":"Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 1.5 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib, 20 mg/m\\^2 on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).","id":"OG002","title":"Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib"}],"paramType":"NUMBER","populationDescription":"Efficacy-evaluable population included all response evaluable participants, i.e., those who received at least one dose of one of their assigned study treatments and had at least one baseline and one on-treatment tumor assessment or those who had one tumor assessment at baseline and discontinued their treatment for any reason before their first on-treatment tumor assessment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 15.2 months","title":"Investigator-assessed Complete Response Rate (CRR) / Stringent Complete Response Rate (sCRR) Per IMWG Response Criteria","type":"PRIMARY","unitOfMeasure":"percentage of participants"}